• Fathima Jabbar
• Dr Prasobh G R
• Dr Sree Lekshmi R S

Pulmonary alveolar microlithiasis (PAM) is a rare fascinating lung disease characterized by intra-alveolar calcium deposits or the accumulation of hydroxyapatite microliths inside the lumen of the alveolar areas. PAM is discovered incidentally on radiographs carried out for other purposes on patients and the typical disease course is characterized by slowly modern respiratory insufficiency over a decade. The etiology of the ailment is still idiopathic and many authors have supposed that an inherited neighborhood enzymatic defect is responsible for calcium deposition. A recent discovery in PAM patients revealed the deficiency of the sodium -phosphate co-transporter Npt2b (SLC34A2, NPY2b, NaPi-2b), is the cause of PAM and has opened a window into the pathogenesis. Powerful animal models are developed which can serve as preclinical models that inform our approach to the management of disease and treatment. Here we review the epidemiology, etiology, radiographic and pathologic features,and clinical management strategies for PAM

Pulmonary alveolar microlithiasis, sodium phosphate co-transporter NPT2b.

"Pulmonary Alveolar Microlithiasis: A Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.9, Issue 12, page no.f810-f818, December-2022, Available :http://www.jetir.org/papers/JETIR2212601.pdf

"Pulmonary Alveolar Microlithiasis: A Review", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.9, Issue 12, page no. ppf810-f818, December-2022, Available at : http://www.jetir.org/papers/JETIR2212601.pdf